Fig. 6

Two months of treatment with ECB-BDNF in App^NL−G−F mice lowered Aβ plaque deposition around implant proximity. A Schematic representation of ECB implantation timeline in cohort 2. B BDNF released from the ECB-BDNF devices at pre-implantation (pre-impl.) and after explantation (post-expl.) in cohort 2. C Representative immunofluorescence staining of BDNF levels, microglia (Iba1), and astrocytes (GFAP) in mouse brain slices from non-implanted and ECB-BDNF implanted mice (n = 2). D Analysis of Aβ plaque deposition staining in the proximity and distal areas surrounding ECB-BDNF devices (n = 4). Scale bar 300 μm. Data are represented as mean ± S.E.M. Data were analyzed by unpaired Student’s t-test